Evidence-Based Complementary and Alternative Medicine

Review Article

Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review

Table 2

GRADE evidence profile of clinical efficacy.


Studies (follow-up time)	Quality assessment					Quality	Importance
	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations

ORR (4–16 weeks)	Serious¹	No serious inconsistency	No serious indirectness	No serious imprecision	None	⊕⊕⊕Ο	Critical
						MODERATE

DCR (4–16 weeks)	Serious¹	No serious inconsistency	No serious indirectness	No serious imprecision	None	⊕⊕⊕Ο	Critical
						MODERATE

SR (1–3 years)	Serious¹	No serious inconsistency	No serious indirectness	No serious imprecision	None	⊕⊕⊕Ο	Critical
						MODERATE

KPS (4–16 weeks)	Serious¹	No serious inconsistency	No serious indirectness	No serious imprecision	None	⊕⊕⊕Ο	Critical
						MODERATE

The decline of leucocyte count (4–8 weeks)	Serious¹	No serious inconsistency	No serious indirectness	No serious imprecision	None	⊕⊕⊕Ο	Important
						MODERATE

Gastrointestinal dysfunction (4–16 weeks)	Serious¹	No serious inconsistency	No serious indirectness	No serious imprecision	None	⊕⊕⊕Ο	Important
						MODERATE

The hepatic and renal dysfunction (4–16 weeks)	Serious¹	Serious²	No serious indirectness	No serious imprecision	None	⊕⊕ΟΟ	Important
						LOW

¹Most domains had unclear methodological bias risk; ²the included studies had inconsistent result, and therefore the evidence was rated down by one level.